AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B at FLORetina 2024
December 09, 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa USH1B
AAVantgarde announces oral presentation of LUCE-1 clinical study at FLORetina 2024 annual meeting
December 03, 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde announces oral presentation of LUCE-1 clinical study at FLORetina 2024 annual meeting
AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081 for the Treatment of Usher Syndrome Type 1B Retinitis Pigmentosa
December 02, 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081 for the Treatment of Usher Syndrome Type 1B Retinitis Pigmentosa
AAVantgarde Founder and Chief Scientific Officer, Professor Alberto Auricchio, is elected as President of the European Society of Gene and Cell Therapy
October 28, 2024 03:00 ET
|
AAVantgarde Bio
AAVantgarde Founder and Chief Scientific Officer, Professor Alberto Auricchio, is elected as President of the European Society of Gene and Cell Therapy
AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer
October 21, 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer
AAVantgarde announces 3 oral presentations at ESGCT 2024 annual meeting
October 08, 2024 02:00 ET
|
AAVantgarde Bio
MILAN, Oct. 08, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector...
AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B
September 16, 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study
AAVantgarde appoints Dr. Jayashree Sahni as Chief Medical Officer
September 09, 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde appoints Dr. Jayashree Sahni as Chief Medical Officer
AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B
May 03, 2024 03:00 ET
|
AAVantgarde Bio
AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
April 24, 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting